Par Pharmaceutical is headquartered in Woodcliff Lake, New Jersey, with main R&D and manufacturing facilities in Spring Valley, New York, and additional R&D facilities in Somerset, New Jersey.

Par's Generics Division is committed to providing high-quality pharmaceuticals that are affordable and accessible to patients. Par ranks as the 7th largest generic drug company in the U.S. according to IMS data. The company currently manufactures, markets or licenses generic prescription drugs in 85 product families. The Generics Division is focused on the development of products that have limited competition and longer life cycles.

Par's Branded Products Division was launched in 2005 with the approval of Megace® ES. Megace ES is indicated for the treatment of anorexia, cachexia, or unexplained significant weight loss in AIDS patients and was conceived and developed by Par's Generic Division and launched in 2005. In September 2007, Par's Branded pharmaceuticals business was renamed Strativa Pharmaceuticals. Strativa has in-licensed various late-stage development drugs with the goal of leveraging Strativa's experienced branded management team and a strong commercial infrastructure that is deployed to over 80% of the treaters in the U.S. supportive care segment.

Par has a successful track record of innovative partnerships that leverage our expertise in R&D, Regulatory, Legal, and Sales & Marketing. We have built strong, successful partnerships with pharmaceutical companies of all sizes, including large branded multinationals, foreign and domestic generic players, formulation technology specialists, off-shore development and manufacturing companies, and virtual start-up companies. Par actively seeks partnerships involving value-added generic products (first-to-file opportunities, difficult formulations, etc)